Erez Aminov

Strategic architect of MIRA’s pipeline. Drives capital markets and development strategy.

Itzchak Angel, Ph.D

More than 40 years in drug discovery. Former Head of Pharmacology at Sanofi/Synthelabo. Architect of the Ketamir-2 program and MIRA’s pipeline.

Andriy Mushak

More than 20 years of SEC reporting and accounting experience. Leads financial reporting, compliance, and accounting.